Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.35 |
| ▸ | CDK9 | P50750 | 4/20 | 0.35 |
| ▸ | CASP1 | P29466 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13531173 | 0.85 | PPARD (0.41) | TAAR1PPARDMAPK1KMT2AALDH1A1 | |
| SCHEMBL13531115 | 0.84 | TAAR1 (0.47) | TAAR1PPARDCCNT1CDK9TSHR | |
| SCHEMBL13531116 | 0.82 | ALDH1A1 (0.37) | PPARDKMT2AALDH1A1TSHR | |
| SCHEMBL13531124 | 0.80 | GAA (0.39) | PPARDKMT2AALDH1A1CASP1TSHR | |
| SCHEMBL7393069 | 0.76 | GFER (0.45) | PPARDCYP3A4TSHR | |
| SCHEMBL9538080 | 0.74 | MAPK1 (0.59) | TAAR1MAPK1KMT2AALDH1A1CYP3A4 | |
| SCHEMBL13530622 | 0.73 | CCNT1 (0.42) | MAPK1KMT2AALDH1A1CCNT1CDK9 | |
| SCHEMBL12401813 | 0.73 | ALDH1A1 (0.50) | TAAR1MAPK1KMT2AALDH1A1CASP1 | |
| SCHEMBL5953121 | 0.72 | ALDH1A1 (0.54) | TAAR1MAPK1KMT2AALDH1A1CASP1 | |
| SCHEMBL16252171 | 0.71 | TAAR1 (0.42) | TAAR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247488-A1 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | CANNIZZARO CARINA | 2009-10-01 | — | — | US | disclosed |
| US-7470724-B2 | Phosphonate compounds having immuno-modulatory activity | GILEAD SCIENCES, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-7452901-B2 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7432261-B2 | Anti-inflammatory phosphonate compounds | GILEAD SCIENCES, INC. (US) | 2008-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247488-A1 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | PHOSPHO1, TNF, PTGES | TAAR1 4363/4885PPARD 197/4885MAPK1 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.